Based on the hypothesis that long-term feto-maternal microchimerism is associated with acquired immunologic hyporesponsiveness to non-inherited maternal antigens (NIMA) or inherited paternal antigens (IPA), several groups have recently reported successful cases of non-T-cell-depleted hematopoietic stem-cell transplantation (SCT) from HLA-haploidentical family members mismatched for NIMA. In this study, we examined the outcomes of 35 patients with advanced hematologic malignancies who underwent HLA-2 or 3-antigen-incompatible SCT from a microchimeric NIMA-mismatched donor.
Introduction
The lack of donor availability has been a major limitation to the widespread use of allogeneic hematopoietic stem-cell transplantation (SCT), which is a curative treatment for various hematologic malignancies, bone marrow failure syndromes, and genetic disorders. Despite the presence of an increasing pool of unrelated volunteer donor registries, a significant proportion of patients who need allogeneic SCT is not able to find a histocompatible donor because of the inheritance of a rare or private HLA haplotype. Currently, unrelated umbilical-cord blood is validated as an alternative stemcell source allowing less HLA restriction for children with malignant diseases 1 .
However, its application to adult recipients is still associated with a high probability of early non-relapse mortality mostly due to delayed or unsuccessful engraftment 2 , although a few centers have reported encouraging results [3] [4] [5] [6] .
Genetically HLA-haploidentical family members are more readily accessible to most of the patients who fail to find an HLA-compatible related or unrelated donor.
However, transplants from such donors are limited by a number of historical barriers such as intractable graft-versus-host disease (GVHD) or graft failure 7, 8 . To overcome these problems especially in transplants from HLA-2 or 3-antigen-mismatched donors, extensive efforts have been made over the past decade including partial T-cell-depletion combined with intensive immunosuppression 9 , megadose CD34 + cell transplantation 10 , and ex vivo anergy induction 11 . Although these studies clearly became the leads to safer and more effective ways to undergo highly HLA-disparate transplantations, their introduction into routine clinical practice still awaits further validation.
An alternative way to overcome histocompatible barriers in transplantation medicine would be to identify "permissible" or "acceptable" HLA mismatches 12 . The concept that some mismatches are not harmful in terms of allograft acceptance was originally proposed from earlier observations that different HLA mismatches had different influences on survival rates of kidney allografts 13, 14 . In this scenario, more attention should be focused on the less immunogenicity of the non-inherited maternal HLA antigens (NIMA) to which one had been previously exposed in utero. In the late 1980s, Claas and colleagues in Leiden reported that about half of the patients who received multiple blood transfusions as adults exhibited reduced alloreactivity against NIMA, while they had much higher reactivity against non-inherited paternal antigens (NIPA) 15 .
The clinical significance of this observation was later revived through two retrospective
analyses showing the superior long-term survival rates in NIMA-mismatched kidney allografts, although the introduction of new immunosuppressive drugs appeared to obscure such effects 16, 17 . Furthermore, another study performed by the International Bone Marrow Transplant Registry (IBMTR) also revealed that bone marrow transplants from NIMA-mismatched siblings were significantly associated with a lower incidence of grades II to IV acute GVHD (aGVHD) when compared with those from the other HLA-mismatched familial donors 18 . However, the true existence of such tolerogenic "NIMA effect" has still been under the subject of debate due to lack of the knowledge on the underlying immunologic mechanisms 19, 20 .
Recently Importantly, they also demonstrated that the tolerant mice had higher levels of maternal cell microchimerism after their birth as compared with the non-tolerant mice, suggesting
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From the role of long-term maternal microchimerism for the induction and maintenance of NIMA-specific allo-tolerance. In this context, we previously found that more than two thirds of healthy adults have hematopoietic cell microchimerism presumed to be of maternal or fetal origin, and proposed that the presence of such microchimerism might have beneficial effects on the transplant outcome by reducing host-versus-graft (HVG) or graft-versus-host (GVH) alloreactivity not only against NIMA, but also against including the clinical severity of aGVHD and cGVHD were thoroughly reviewed by two independent physicians. All the patients were longitudinally followed up until and IPA haplotypes were deduced from the HLA typing results obtained from family members of two or three generations. The presence of the recipient-specific long-term microchimerism presumed to be of maternal or fetal origin was confirmed in all the donors with IPA or NIMA-specific nested polymerase chain reactions using sequence-specific primers as previously described 26, 31 . No patients were reported to be positive for anti-donor-lymphocyte antibodies before transplantation.
Preparative regimens, transplantation procedures, and GVHD prophylaxis
Recipients were prepared for transplantation with various conditioning regimens employed by each center. Regimens which included more than 4 Gy of total-body irradiation or more than 8 mg/kg of busulfan were considered to be myeloablative (standard-intensity regimens). According to this definition, 21 patients (60%) received standard-intensity regimens based on 6 to 12 Gy of total-body irradiation (TBI) (median Post-transplant G-CSF was administered to 28 patients. Twenty-three patients (63%)
received GVHD prophylaxis consisted of tacrolimus and methotrexate (MTX). The other regimens used for GVHD prophylaxis included tacrolimus alone in 4 (11%), tacrolimus plus corticosteroids or mycophenolate mofetil in 2 (6%), and tacrolimus plus MTX plus corticosteroids in 6 (16%). All the patients received standard antibiotics, antifungal agents, and blood products according to the protocols of each institution.
Assessment of engraftment, GVHD, and survival
The date of neutrophil recovery was defined as the first of 3 consecutive days in which the absolute neutrophil count (ANC) exceeded 0.5 x10 9 /L. The date of platelet recovery was defined as the first of 7 consecutive days during which the non-transfused platelet count was at least 20x10 9 /L. Donor cell engraftment was determined on marrow samples using sex-chromosome-specific fluorescence in situ hybridization (FISH) or quantitative PCR of informative short tandem repeat regions in the recipient and donor.
Complete donor chimerism was defined as the detection of >95% donor cells in the marrow nucleated cell populations. Late graft failure was defined among the patients who attained neutrophil engraftment as a decline of ANC to less than 0.5 x10 9 /L for at least 7 consecutive days with evidence of severe hypocellularity of bone marrow confirmed by histopathological examination. Acute and chronic GVHD were diagnosed and graded according to standard criteria 32, 33 . All the patients who had evidence of donor cell engraftment were considered to be evaluable for aGVHD, excluding 1 patient who developed life-threatening multiple organ failure before engraftment. Chronic GVHD was evaluated in patients who survived without relapse or disease progression for at least 100 days after transplantation. Overall survival was applied to all the patients and measured from the date of transplantation to the date of death from any cause.
Event-free survival was applied to the patients who survived in remission for at least 30 days after transplantation and measured from the date of transplantation to the date of relapse or death. Patients were censored at the time of the last follow-up.
Statistical analysis
Probabilities and their 95% confidence intervals (CI) by binomial distribution for obtaining neutrophil recovery were calculated using the number of subjects obtaining target values as numerator and total number of subjects as denominator. Cumulative incidence curves were used to obtain probability of aGVHD which has survival event as a competing risk 34 . Kaplan-Meier estimates were applied to obtain the probability of survival at specific time points, and difference in survival was tested by the log-rank test. 
Results

Characteristics of the study patients
The characteristics of the patients, the donors, and the transplantation procedures are summarized in Table 1 (Table 1) .
Engraftment
All the patients attained successful neutrophil recovery at a median of 14 days (range, 9 to 21 days). Analyses of donor cell chimerism using marrow aspirates were available in 33 patients, excluding 2 patients who could not be assessed due to early toxic death. All the 22 evaluable patients receiving standard-intensity regimens and 10 of 11 patients conditioned with reduced-intensity regimens were shown to achieve complete donor chimerism between days 14 and 94 after transplantation. One patient with chemorefractory AML who received reduced-intensity conditioning had mixed chimerism due to the persistence of leukemic cells in the peripheral blood. Recovery of platelet counts of more than 20 x10 9 /L was observed in 31 patients (89%) at a median of 14 days (range, 0 to 104 days). The principal causes of failure of platelet recovery in the remaining 4 patients were early toxic death in 2, early relapse in 1, and thrombotic microangiopathy in 1. No late graft failure was reported.
Graft-versus-host disease
Acute GVHD was evaluable in 34 patients. The respective number of patients who developed grade 0, I, II, III, or IV aGVHD was 6 (18%), 9 (26%), 11 (32%), 5 (15%), and 3 (9%). One patient assigned to grade II developed treatment-resistant aGVHD after the early cessation of tacrolimus on day 45 and the subsequent donor lymphocyte infusions for relapse. Ten other patients who developed grade II and 2 of 5 patients who
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From developed grade III aGVHD completely responded to the primary treatment with corticosteroids. The cumulative incidence estimate of grades II-IV and III-IV aGVHD among all evaluable patients by 100 days after transplantation was 56% (95%CI, 38%-71%) and 22% (95%CI, 10%-37%), respectively. In univariate analysis, the incidence of grades III-IV aGVHD was not significantly associated with the number of mismatched HLA antigen in either GVH or HVG direction, age of patient at SCT, donor-patient sex-combination, disease status at SCT, type of conditioning, and regimen of GVHD prophylaxis (Table 2 ). However, it was notable that transplantations from offspring or sibling donors (GVH target=NIMA; "NIMA-targeted"group) had a lower risk of developing grades III to IV severe aGVHD when compared with those from maternal donors (GVH target=IPA; "IPA-targeted"group) (P=.04). It seems unlikely that the difference in the risk of developing severe aGVHD between the IPA-targeted and NIMA-targeted transplantations originate from other factors in each patient group, because two groups had similar background characteristics except a few variables (Table 1) and NIMA mismatch in the GVH direction was still associated with a lower risk for grade III-IV aGVHD after adjusted by a multivariate regression model (P=.03) ( Table 2) . A similar result was obtained by another multivariate model including donor multiparity (multiparous females vs other females or males) instead of simple donor-recipient sex-mismatch as a potential risk factor for severe aGVHD. The respective cumulative incidence of grades II-IV aGVHD in the NIMA-targeted group and IPA-targeted group was 50% (95%CI, 27%-69%) and 64% (95%CI, 34%-83%) (Figure 2A ), whereas those of grade III-IV was 10% (95%CI, 2%-26%) in the NIMA-targeted group and 38% (95%CI, 15%-60%) in the IPA-targeted group ( Figure   2B 
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Chronic GVHD was observed in 19 of 23 evaluable patients (83%) who survived without evidence of relapse for at least 100 days after transplantation; 6 patients had limited-stage disease and the remaining 13 patients had extensive disease. Extensive cGVHD occurred in 4 of 9 evaluable patients (44%) in the IPA-targeted group, and 9 of 14 evaluable patients (64%) in the NIMA-targeted group.
Relapse and causes of death
Twenty deaths were reported until the time of last follow-up. Primary causes of death were disease-related in 9 and transplantation-related in 11 (Table 3) . Two patients died from multiorgan failure due to regimen-related toxicity by day 30. were disease-free, with a median follow-up of 20 months (range, 8 to 37 months). The estimated probability of survival at 3 years after transplantation was 38% (95% CI, For personal use only. on September 24, 2017. by guest www.bloodjournal.org From 17%-60%) for the whole cohort ( Figure 3A ). The survival rate for patients who underwent transplantation in remission or chronic phase was 62% at 3 years, compared with 22% at 2 years for those who had a chemorefractory disease at transplant (P=0.17) ( Figure 3B ). When the analysis was confined to the 29 patients who survived in remission for at least 30 days after transplantation, the estimated event-free survival at 3 years was 47% (95% CI, 29%-66%). Notably, 5 of the 22 chemoresistant patients (23%) were alive in continuous remission for more than 18 months after transplantation (2 with relapsed or primary refractory AML, 1 with relapsed ALL, 1 with CML in blastic phase, and 1 with primary refractory diffuse large B-cell lymphoma). All surviving patients in remission had a Karnofsky score of 80 or more. In univariate analysis, no factors including the degree of HLA incompatibility and the type of GVH target (IPA vs NIMA) showed significant association with survival.
For
Discussion
In this study, we evaluated the feasibility of T-cell-replete HLA-haploidentical SCT from a microchimeric NIMA-mismatched family member (NIMA-complementary SCT) in terms of engraftment, incidence and severity of GVHD, and the events which affected survival among a selected cohort of patients with advanced hematologic malignancies. Our analyses revealed previously unknown benefits of non-T-cell-depleted SCT based on such novel criteria for HLA-haploidentical donor selection, although the heterogeneity of these transplantations currently demands careful interpretation of each result. First, in contrast to the previous experiences of "non-megadose" CD34 + -selected SCT or umbilical-cord blood transplants in adults 2, 36 , our series of patients had a high probability of prompt hematopoietic engraftment following both standard-intensity and reduced-intensity conditioning regimens. Second, regardless of the great degree of HLA disparity between donor and recipient, 27 of the 34 evaluable patients (79%) did not develop treatment-resistant aGVHD using standard GVHD prophylaxis based on tacrolimus. Moreover, although most of the patients had an advanced or chemorefractory disease at the time of transplantation, a significant proportion of these patients still remained alive and disease-free with a relatively good performance status, yielding a product-limit survival estimate of 38% at 3 years.
Additionally, it is less likely that these favorable results might be attributable to the relative homogeneity of the histocompatibility antigens among the Japanese populations, because the Japanese nationwide analyses of T-cell-replete HLA-2 or 3-loci-mismatched SCT without considering NIMA compatibility also revealed a higher incidence of severe aGVHD and inferior survival rates as have been previously reported from the non-Japanese centers 37,38 .
For Furthermore, a retrospective study performed by the JSHCT showed that even adult patients who received SCT from maternal donors had a better survival rate when compared to those receiving paternal blood and marrow grafts. Although there have been conflicting reports on the true presence of such tolerogenic or protective effects among the "mother-child union", recent studies using murine models have demonstrated the involvement of multiple mechanisms 44 , and highlighted the role of regulatory T cell subsets and the long-lasting feto-maternal microchimerism in the establishment of IPAor NIMA-specific hyporesponsiveness 21, 45 .
The phenomenon of long-term feto-maternal microchimerism, which is naturally acquired as a result of two-way cell traffic between mother and fetus during pregnancy 22 ,
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From was first described in the late 1990s through the development of PCR-based techniques that are capable of detecting less than 0.01% of microchimeric cells among the background cells 46, 47 . Earlier studies have extensively investigated the role of such microchimerism in the pathogenesis of various autoimmune diseases, however, it has been difficult to demonstrate a true causal link, because a number of healthy individuals were also shown to be naturally microchimeric 48, 49 . Given the common incidence of feto-maternal microchimerism among healthy subjects without any autoimmune attacks, we subsequently raised a hypothesis that long-term acceptance of maternal cells in antigens between donor and recipient. However, this striking finding does not seem to be a definitive "proof of principle", because 8 of the 34 evaluable patients (24%) still experienced severe grade III-IV aGVHD, suggesting that the presence of the recipient-specific microchimerism in the donor is a relative indicator, rather than a hallmark, of appropriate NIMA-mismatched donor selection. Therefore, for the "NIMA-complementary" transplants to be safer and more feasible, it is essential to establish additional methods for identifying the NIMA-mismatched donor-recipient pairs who are at high risk for developing severe GVHD.
It is important to note here that 6 of the 14 evaluable patients (43%) receiving SCT from a microchimeric maternal donor developed grade III or IV aGVHD, and 3 of them became fatal. Although the result should be interpreted with caution due to small size of this study, multivariate analysis revealed that the only factor significantly associated Finally, the type of stem-cell source might also have an influence on the development of aGVHD and cGVHD after NIMA-complementary SCT. Transplantation of unmanipulated PBSC has been reported to be associated with a higher incidence of cGVHD, particularly of extensive type, as compared with bone marrow among SCT from HLA-identical siblings 57,58 . Apparently high incidence of cGVHD in our series of patients might be partly explained by the fact that most of them had received PBSC allografts, although whether the difference in quantity or characteristics of microchimeric cells contained in the marrow or PBSC graft may affect the development of cGVHD has yet to be investigated.
In conclusion, our results showed that T-cell-replete HLA-haploidentical SCT from a microchimeric NIMA-mismatched family member can reconstitute long-term hematopoiesis with acceptable rates of treatment-resistant GVHD, and also can induce sustained remission in selected patients with chemorefractory hematologic malignancies.
Since this approach may greatly increase the donor availability and open a way to more appropriate donor selection in HLA-haploidentical SCT, future researches are required to more precisely evaluate NIMA or IPA-specific allo-tolerance and to identify genetic factors which are associated with GVHD and non-relapse mortality in a given NIMA-mismatched donor-recipient pair.
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